A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1067 participants.

Also called NCT01493557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,067 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01493557
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01493557. Randomized; no masking; primary purpose prevention. Start 2011-12 (registry gives no type); primary completion 2014-07 (actual). Results posted on 2015-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Intervention (Drug)
pantoprazole
Intervention (Drug)
Pradaxa (dabigatran etexilate)
Intervention (Drug)
Pradaxa, within 30 minutes after a meal
Intervention (Drug)
Pradaxa (dabigatran etexilate)
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct01493557
Content hash
776f2598417cbc7a122302c618a0cacf500d86e5ee0db5950af9761469a15dc3